Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (287)	11/28/1998 12:39:00 AM
From: aknahow	Read Replies (1) \| Respond to of 712

Glad your here. The problem I have with CORR is my being unable to see why reducing the death rate or heart attack rate from 15.7 per thousand down to 14.2 is dramatic. I understand that the FDA thought it was worth approving and that what I am dealing with is my own inability to really see this as a significant difference. Or in other words I see 998.5 out of 1000 patients getting the drug with no difference in the outcome. Only 1.5 of the 1,000 given the drug actually had his outcome. I do find the 10K of great interest and have been impressed with the post of some of those in a position to actually know Integrilin is being used at increasing rates. ".. the combined incidence of death or heart attack at 30 days was significantly reduced from 15.7 percent with current management strategies alone to 14.2 percent with INTEGRILIN added to current management strategies in the overall study population of 10,948 patients from 726 hospitals in 27 countries. On average, for every 1,000 patients treated with INTEGRILIN, 15 events of death or heart attack were prevented."